# AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

> **NCT00071006** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** AG-013736 (Axitinib)

## Key facts

- **NCT ID:** NCT00071006
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071006, "AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00071006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*